Experiences with
Chronic leukaemia5,754 public posts
Review article summarises management strategies for those with CLL harbouring complex karyotype
On 6 January 2025, the journal [i]BJ Haem[/i] published a review article titled [i]Management strategies for patients with lymphocytic leukaemia harbouring complex karyotype[/i] written by a team from Padua, Italy.
Additional insights from the 2023 Global Leukemia Experience Survey - CLL specific findings, unmet needs and recommendations for action
As chronic leukaemia progression is slower than acute, the symptom onset can be subtle and take years to have an impact on quality of life. Improving symptom awareness and early health seeking behaviour in the general population and targeted education for primary care clinicians may address this.
Want to take advantage of all our features? Just log in!
or
Financial Assistance for Patients with Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL)
Financial Assistance for Patients with Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL) https://www.lls.org/support-resources/financial-support/co-pay-assistance-program
If you are diagnosed with CLL or SLL, you may qualify for The Leukemia & Lymphoma Society's Co-Pay Assistance
Chemo-free treatment with acalabrutinib can benefit CLL/SLL patients never treated before: a plain language summary of the ELEVATE-TN study
The ELEVATE-TN international study commenced in September 2015. The plain language article illustrates how this clinical trial was established and run to determine whether targeted therapy arms using acalabrutinib, a Bruton's Tyrosine Kinase inhibitor ( BTKi), with or without obinutuzumab, would outperform
Improving Treatment Options for Patients with Double Refractory CLL - patients who progressed after treatment with both cBTKis and BCL2i
[i] Abstract[/i]
[i][/i]
[i]The proliferation and survival of chronic lymphocytic leukemia (CLL) cells are heavily dependent on B-cell receptor (BCR) signaling and resistance to apoptosis. Approvals of multiple covalent Bruton's tyrosine kinas inhibitors (cBTKis) as well as the B-cell lymphoma
BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL
Here's a welcome article that explains all about BTK degraders; the next class of BTK drug after the success of the FDA approved covalent BTKis (acalabrutinib/Calquence, ibrutinib/Imbruvica and zanubrutinib/Brukinsa) and non-covalent BTKi pirtobrutinib/Jaypirca.
[i][/i]
[i]"Oral therapies targeting
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Abstract report in New England Journal of Medicine Published February 5, 2025
No real new information here and I'm surprised anyone was recruited for this study as the control arm is chemoimmunotherapy and no account appears to have been taken for unmated IGHV or 17p/TP53 as the patients were
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying CLL patients with early treatment requirement
Most of us would be aware of the prognostic value of the immunoglobulin heavy-chain variable region gene (IGHV) mutation status of our CLL (See https://healthunlocked.com/cllsupport/posts/private/146164102/the-fascinating-history-of-the-importance-of-ighv-mutation-status-in-cll-prognosis-and-treatment